Efficacy News and Research

RSS
Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Antiviral therapy may prevent hepatitis B virus from developing into hepatocellular carcinoma

Antiviral therapy may prevent hepatitis B virus from developing into hepatocellular carcinoma

BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

Cubist Pharmaceuticals publishes positive results from Phase 3 clinical trial of SIVEXTRO

Cubist Pharmaceuticals publishes positive results from Phase 3 clinical trial of SIVEXTRO

Valeant Pharmaceuticals receives approval from FDA for treatment of onychomycosis

Valeant Pharmaceuticals receives approval from FDA for treatment of onychomycosis

Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

Batu Biologics reports FDA development plans for cancer immunotherapeutic vaccine ValloVax

Batu Biologics reports FDA development plans for cancer immunotherapeutic vaccine ValloVax

European Commission approves Boehringer Ingelheim's Pradaxa for prevention of DVT and PE

European Commission approves Boehringer Ingelheim's Pradaxa for prevention of DVT and PE

ImStem successfully treats animal model of multiple sclerosis using hESC

ImStem successfully treats animal model of multiple sclerosis using hESC

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

MolecularHealth launches innovative oncology program for employers

MolecularHealth launches innovative oncology program for employers

Study offers clues to best long-acting injectable antipsychotic use

Study offers clues to best long-acting injectable antipsychotic use

CBO to stop scoring some parts of the health law

CBO to stop scoring some parts of the health law

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

Immune Design begins treatment in LV305 Phase 1 clinical trial for cancer

Edge Therapeutics commences enrollment in second cohort of EG-1962 Phase 1/2 NEWTON study for aSAH

Edge Therapeutics commences enrollment in second cohort of EG-1962 Phase 1/2 NEWTON study for aSAH

Advanced Cancer Therapeutics begins clinical trials of PFK-158 small molecule therapeutic candidate

Advanced Cancer Therapeutics begins clinical trials of PFK-158 small molecule therapeutic candidate

SAGE reports preliminary data from SAGE-547 Phase 1/2 clinical trial for super-refractory status epilepticus

SAGE reports preliminary data from SAGE-547 Phase 1/2 clinical trial for super-refractory status epilepticus

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Thermo Fisher, Cellectis sign agreements on TALEN gene editing technology

Thermo Fisher, Cellectis sign agreements on TALEN gene editing technology

Study calls for more randomized trials on e-cigarettes

Study calls for more randomized trials on e-cigarettes

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.